The Library
Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis
Tools
Tools
Tools
Kihm, L. P., Muller-Krebs, S., Klein, Julia, Ehrlich, G., Mertes, L., Gross, Marie-Luise, Antonysunil, Adaikalakoteswari, Thornalley, Paul J., Hammes, H.-P., Nawroth, P. P., Zeier, M. and Schwenger, Vedat. (2011) Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. Journal of the American Society of Nephrology, Vol.22 (No.5). pp. 914-926. ISSN 1046-6673
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1681/ASN.2010070750
Abstract
Residual renal function and the integrity of the peritoneal membrane contribute to morbidity and mortality among patients treated with peritoneal dialysis. Glucose and its degradation products likely contribute to the deterioration of the remnant kidney and damage to the peritoneum. Benfotiamine decreases glucose-induced tissue damage, suggesting the potential for benefit in peritoneal dialysis. Here, in a model of peritoneal dialysis in uremic rats, treatment with benfotiamine decreased peritoneal fibrosis, markers of inflammation, and neovascularization, resulting in improved characteristics of peritoneal transport. Furthermore, rats treated with benfotiamine exhibited lower expression of advanced glycation endproducts and their receptor in the peritoneum and the kidney, reduced glomerular and tubulointerstitial damage, and less albuminuria. Increased activity of transketolase in tissue and blood contributed to the protective effects of benfotiamine. In primary human peritoneal mesothelial cells, the addition of benfotiamine led to enhanced transketolase activity and decreased expression of advanced glycation endproducts and their receptor. Taken together, these data suggest that benfotiamine protects the peritoneal membrane and remnant kidney in a rat model of peritoneal dialysis and uremia.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RB Pathology R Medicine > RC Internal medicine |
||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine |
||||
| Library of Congress Subject Headings (LCSH): | Peritoneal dialysis, Vascular endothelium, Oxidative stress, Hyperglycemia, Vitamin B1 | ||||
| Journal or Publication Title: | Journal of the American Society of Nephrology | ||||
| Publisher: | American Society of Nephrology | ||||
| ISSN: | 1046-6673 | ||||
| Official Date: | May 2011 | ||||
| Dates: |
|
||||
| Volume: | Vol.22 | ||||
| Number: | No.5 | ||||
| Page Range: | pp. 914-926 | ||||
| Identification Number: | 10.1681/ASN.2010070750 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Gambro (Firm), Worwag Pharma | ||||
| URI: | http://wrap.warwick.ac.uk/id/eprint/40021 |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Actions (login required)
 |
View Item |
